A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Phase
3Span
220 weeksSponsor
Eli Lilly and CompanyIna, Nagano
Recruiting
1-1 of 1